A small molecule ApoE4-targeted therapeutic candidate that normalizes sirtuin 1 levels and improves cognition in an Alzheimer’s disease mouse model
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
A small molecule ApoE4-targeted therapeutic candidate that normalizes sirtuin 1 levels and improves cognition in an Alzheimer’s disease mouse model ; volume:8 ; number:1 ; day:4 ; month:12 ; year:2018 ; pages:1-15 ; date:12.2018
Scientific reports ; 8, Heft 1 (4.12.2018), 1-15, 12.2018
- Urheber
-
Campagna, Jesus
Spilman, Patricia
Jagodzinska, Barbara
Bai, Dongsheng
Hatami, Asa
Zhu, Chunni
Bilousova, Tina
Jun, Michael
Elias, Chris Jean
Pham, Johnny
Cole, Gregory
LaDu, Mary Jo
Jung, Michael E.
Bredesen, Dale E.
John, Varghese
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-018-35687-8
- URN
-
urn:nbn:de:101:1-2019011320402837199411
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Campagna, Jesus
- Spilman, Patricia
- Jagodzinska, Barbara
- Bai, Dongsheng
- Hatami, Asa
- Zhu, Chunni
- Bilousova, Tina
- Jun, Michael
- Elias, Chris Jean
- Pham, Johnny
- Cole, Gregory
- LaDu, Mary Jo
- Jung, Michael E.
- Bredesen, Dale E.
- John, Varghese
- SpringerLink (Online service)
Ähnliche Objekte (12)
Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease
ApoE4: an emerging therapeutic target for Alzheimer’s disease
Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease
Impact of APOE ε4 and ε2 on plasma neurofilament light chain and cognition in autosomal dominant Alzheimer’s disease
Imipramine and olanzapine block apoE4-catalyzed polymerization of Aβ and show evidence of improving Alzheimer’s disease cognition
Domino-like effect of C112R mutation on ApoE4 aggregation and its reduction by Alzheimer’s Disease drug candidate
Apolipoprotein E4 as a Novel Treatment Target for Alzheimer’s Disease
The genetic risk of Alzheimer’s disease beyond APOE ε4: systematic review of Alzheimer’s genetic risk scores
Author Correction: Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease
APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease
Brainstem substructures and cognition in prodromal Alzheimer’s disease
Association of peripheral immunity with cognition, neuroimaging, and Alzheimer’s pathology
Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease
ApoE4: an emerging therapeutic target for Alzheimer’s disease
Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease
Impact of APOE ε4 and ε2 on plasma neurofilament light chain and cognition in autosomal dominant Alzheimer’s disease
Imipramine and olanzapine block apoE4-catalyzed polymerization of Aβ and show evidence of improving Alzheimer’s disease cognition
Domino-like effect of C112R mutation on ApoE4 aggregation and its reduction by Alzheimer’s Disease drug candidate
Apolipoprotein E4 as a Novel Treatment Target for Alzheimer’s Disease
The genetic risk of Alzheimer’s disease beyond APOE ε4: systematic review of Alzheimer’s genetic risk scores
Author Correction: Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease
APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease
Brainstem substructures and cognition in prodromal Alzheimer’s disease
Association of peripheral immunity with cognition, neuroimaging, and Alzheimer’s pathology
Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease
ApoE4: an emerging therapeutic target for Alzheimer’s disease
Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease
Impact of APOE ε4 and ε2 on plasma neurofilament light chain and cognition in autosomal dominant Alzheimer’s disease
Imipramine and olanzapine block apoE4-catalyzed polymerization of Aβ and show evidence of improving Alzheimer’s disease cognition
Domino-like effect of C112R mutation on ApoE4 aggregation and its reduction by Alzheimer’s Disease drug candidate
Apolipoprotein E4 as a Novel Treatment Target for Alzheimer’s Disease
The genetic risk of Alzheimer’s disease beyond APOE ε4: systematic review of Alzheimer’s genetic risk scores
Author Correction: Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease
APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease
Brainstem substructures and cognition in prodromal Alzheimer’s disease